I. Field
Aspects of the present invention relate generally to gamma ray sensors, and more particularly to methods and devices for detecting radioisotope concentration, activity and volume using gamma ray detection with cadmium zinc telluride (CZT) solid state detectors.
II. Background
Diagnostic techniques in nuclear medicine generally use radioactive tracers which emit gamma rays from within the body. These tracers are generally short-lived isotopes linked to chemical compounds which permit specific physiological processes to be studied. These compounds, which incorporate radionuclides, are known as radiopharmaceuticals, and can be given by injection, inhalation or orally. One type of diagnostic technique includes detecting single photons by a gamma-ray sensitive camera which can view organs from many different angles. The camera builds an image from the points from which radiation is emitted, and the image is electronically enhanced and viewed by a physician on a monitor for indications of abnormal conditions.
A more recent development is Positron Emission Tomography (PET), which is a more precise and sophisticated technique using isotopes produced in a cyclotron, where protons are introduced into the nucleus resulting in a deficiency of neutrons (i.e., becoming proton rich).
The nucleus of a radioisotope usually becomes stable by emitting an alpha and/or beta particle (or a positron). These particles may be accompanied by the emission of energy in the form of electromagnetic radiation known as gamma rays. This process is known as radioactive decay.
A positron-emitting radionuclide is introduced into the body of a patient, usually by injection, and accumulates in the target tissue. As the radionuclide decays, a positron is emitted, and the emitted positron combines with a nearby electron in the target tissue, resulting in the simultaneous emission of two identifiable gamma rays in opposite directions, each having an energy of 511 keV. These gamma rays are conventionally detected by a PET camera, and provide a very precise indication of their origin. PET's most important clinical role is typically in oncology, with fluorine-18 (F-18) as the tracer, since F-18 has proven to be the most accurate non-invasive method of detecting and evaluating most cancers. Fluorine-18 (F-18) is one of several positron emitters (including also, Carbon-11, Nitrogen-13, and Oxygen-15) that are produced in a cyclotron and are used in PET for studying brain physiology and pathology, in particular for localizing epileptic focus, and in dementia, psychiatry and neuropharmacology studies. These positron emitters also have a significant role in cardiology. F-18 in FDG (fluorodeoxyglucose) has become very important in detection of cancers and the monitoring of progress in cancer treatment, using PET. A radioactive product such as F-18 in FDG is a specific example of a radiopharmaceutical.
F-18 has a half-life of approximately 110 minutes, which is beneficial in that it does not pose a long-term environmental and/or health hazard. For example, after 24 hours, the radioactivity level is approximately 0.01% of the product when freshly produced in a cyclotron. However, transport time from the production source to clinical use should be minimized to retain a maximum potency for accurate diagnostic value.
Whereas PET cameras are effective in imaging uptake of F-18 present in administered FDG, PET cameras are generally too large and ineffective in production settings where characterization of the source product, and not physiological response, is the goal. There is a need, therefore, for a method and apparatus to timely calibrate the radioactivity of a sample at the production source and time of production or packaging for delivery so that the level of radioactivity is predictably known at the time of use.
The following presents a simplified summary of one or more aspects of a method and apparatus for detecting radioisotope concentration, activity and sample volume.
In one example aspect of the invention, a gamma ray detector may include a gamma ray detecting rod elongated in one direction to a specified length, and a gamma ray shield encapsulating the rod, the shield having an opening opposite an end of the elongated rod to admit gamma rays substantially parallel to the long axis of the elongated rod, wherein the long axis of the rod and the opening are directed toward a volume of gamma ray emitting material observable by the detector on the basis of the length of the elongated rod and the opening in the gamma ray shield.
In another example aspect of the disclosure, an apparatus for detecting a volume concentration and activity of a radionuclide content in a container includes a container of known dimensions for receiving the radionuclide. A first gamma ray detector is arranged below the container with respect to gravity and directed toward the container. A second gamma ray detector is arranged above the container with respect to gravity and opposite the first gamma ray detector, and directed toward the container. Detection circuitry and a processor are coupled to the first and second gamma ray detectors, wherein the processor is configured to measure radiation intensity received at the first and second gamma ray detectors and determine a level of content of radionuclide in the container on the basis of the radiation detected by the first and second gamma ray detectors.
To the accomplishment of the foregoing and related ends, the one or more example aspects comprise the features hereinafter fully described and particularly pointed out in the claims. The following description and the annexed drawings set forth in detail certain illustrative aspects of the one or more aspects. These aspects are indicative, however, of but a few of the various ways in which the principles of various aspects may be employed and the described aspects are intended to include all such aspects and their equivalents.
These and other sample aspects of the invention will be described in the detailed description that follow, and in the accompanying drawings, wherein:
In accordance with common practice, some of the drawings may be simplified for clarity. Thus, the drawings may not depict all of the components of a given apparatus (e.g., device) or method. Finally, like reference numerals may be used to denote like features throughout the specification and figures.
Various aspects of methods and apparatus are described more fully hereinafter with reference to the accompanying drawings. These methods and devices may, however, be embodied in many different forms and should not be construed as limited to any specific structure or function presented throughout this disclosure. Rather, these aspects are provided so that this disclosure will be thorough and complete, and will fully convey the scope of these methods and apparatus to those skilled in the art. Based on the descriptions herein teachings herein one skilled in the art should appreciate that that the scope of the disclosure is intended to cover any aspect of the methods and apparatus disclosed herein, whether implemented independently of or combined with any other aspect of the disclosure. For example, an apparatus may be implemented or a method may be practiced using any number of the aspects set forth herein. In addition, the scope of the disclosure is intended to cover such an apparatus or method which is practiced using other structure, functionality, or structure and functionality in addition to or other than the various aspects of the disclosure set forth herein. It should be understood that any aspect of the disclosure herein may be embodied by one or more elements of a claim.
In a radiopharmaceutical production facility, a cyclotron may be used to prepar a bolus of a material containing a radioisotope of interest which is delivered to a synthesis system. The radioisotope may emit one or more kinds of radiation, including electrons, positrons, gamma rays/x-rays, protons, neutrons, alpha particles, and other possible nuclear ejecta. In one example, a radioisotope, when added to other materials to be administered to a subject, may emit a positron, which then annihilates with an electron, for example, in human tissue, to produce gamma rays.
Aspects of the current invention describe a gamma ray detector and methods of measuring the activity, concentration, and volume of a liquid radionuclide as it fills or is drained from a container. In the production of radiopharmaceuticals, the radionuclide may be introduced into a molecular vehicle by chemical synthesis to produce the radiopharmaceutical. Various dosage, concentration, activity and volume requirements for differing medical applications may generally result in splitting, dilution and redistribution of the radioisotope for the production of the various radiopharmaceuticals, wherein a sensor monitors the various production processes.
According to various aspects, the sensor 100 can function accurately as a spectroscopic gamma energy sensor, particularly when the element 110 is CZT. However, geometric aspects may be considered. In conventional use of CZT as a gamma ray detector, the CZT element 110 may be a thin platelet, sometimes arranged in multiples to form arrays for imaging, generally perpendicularly to the source of gamma ray emission. Therefore, gamma rays of differing energies all traverse a detector element of substantially the same thickness. While absorption of the gamma ray may generally be less than 100% efficient, higher energy gamma rays may liberate more electron-hole pairs than lower energy gamma rays, producing a pulse of greater height. The spectrum and intensity of gamma ray energies may thus be spectroscopically determined by counting the number of pulses generated corresponding to different pulse heights.
According to various aspects, because higher energy photons may travel a greater distance in the CZT rod 110 before complete absorption, it is advantageous for the CZT rod 110 to be greater in length in a direction longitudinally (i.e., a long axis) intersecting a known source volume of radionuclide being measured. Gamma rays incident on the CZT rod off or transverse to the long axis may not be fully absorbed, and thus, the CZT rod may not be as sensitive a detector of such gamma rays as a result. Thus, according to various aspects, elongating the CZT rod in one direction introduces a degree of collimation and directional sensitivity along the extended direction.
According to various aspects, the absorption coefficient for 511 keV gamma ray absorption in CZT is μ=0.0153 cm2/gm. The absorption probability as a function of μ, density ρ (=5.78 gm/cm3) and penetration distance h is
P(μ,h)=1−e−μρh.
Therefore, the ratio of absorption in a 10 mm length of CZT to a 1 mm length is
That is, the directional sensitivity for gamma ray detection of CZT at 511 keV along the 10 mm length of the detector is nearly 10 times greater than in the 1 mm thick transverse direction.
Referring to
The processing system 450 may be distributed across a network to facilitate, for example, efficient use of computing resources to serve a plurality of detectors 100 and containers 415. The division of the processing system 450 across the network may be selected at any of several points. For example, one or more access nodes (not shown) and network links (not shown) may be placed between the dual channel analog-to-digital converter (ADC) 456 and the FPGA 458, in which case the FPGA 458 and the computing platform PC 460 may be remotely located across the network. Alternatively, the access nodes and network links may be located between the FPGA 458 and the PC 460. It should be understood that other network linking arrangements between the detectors 100 and computing and control resources may be configured. The PC 460 may also be a network configured computing resource, which may also be distributed across one or more networks. For example, the computing resource PC 460 may include a server, memory, and other accessories, also located remotely from each other across the one or more networks to provide the operational control of the plurality of detectors 100 coupled to respective containers 415.
The count rates are then linearized (in process block 606 for each respective detector 100-t, 100-b). The linearization process may include statistical or calibration-based correction, for example, when the count rate becomes so high that pulses may overlap, an effect referred to as “pile up.”
The measured count rate, as counted by the detector and associated electronics, may become lower than the true count rate at high count rates. This is caused by effects in the bias circuitry, crystal, and the electronics. In the bias circuitry and crystal, a high photon flux can cause a shift in the spectral response (as a decreased photopeak to background ratio) which can cause undercounting. Also, the pulse width (governed by the crystal and preamplifier characteristics) along with the pulse counting electronics can have an impact on linearity. At high count rates, pulses can pile up and double or triple pulses may be combined and counted as one instead of two or three separate pulses respectively. This is exacerbated when the pulse width is increased or the counting electronics is too slow to count fast pulse rates (long retrigger times, etc.).
To linearize the count rate, a nonlinearity calibration is performed, along with implementing a look-up table or nonlinearity correction equation. To perform calibration, a high activity sample (e.g., having a maximum expected activity) is placed in front of each sensor and allowed to decay. Data is then collected over several half-lives until the count rate is low (i.e., in the linear range where no pulse pile up occurs). Curve fitting is then performed (e.g., polynomial, Lambert-W, etc.) to describe the relationship between true count rate and the measured count rate. Once established, the curve for each sensor (detector and electronics) can be used in a look-up table or equation-based correction to linearize measurements made.
Accordingly, a correction may be applied on a calibration basis to correct for an undercounting of pulses due to pulse overlap. If a background count has been detected (such as, for example, before the container is filled), a command may be issued for each detector rate to read the background rate (in process blocks 608-t, 608-b, whether from a look-up table, a previous reading from the detectors prior to filling the container, etc.). The background rates are subtracted (in process blocks 610-t and 610-b) from the respective linearized count rates.
The ratio of the resulting “adjusted” counting rates is computed (in process block 612) and the logarithm of the ratio is computed (in process block 613) which, as it happens is approximately linear in proportion to the fill level of the container 415. In one embodiment, the log ratio measurement may be referred to a lookup table to compute the fill volume of the container (as in process block 614). The fill volume depends on a known value of the shape, cross-section and height of the container 415. The adjusted count rate for each detector is compared with the computed volume to determine the lookup activity (in process blocks 616-t and 616-b) for each respective detector 100-t, 100-b. The outputs to the PC 460 include the top activity level, bottom activity level, and container volume.
According to various aspects,
Computer programs (also referred to as computer control logic) are stored in main memory 908 and/or secondary memory 910. Computer programs may also be received via communications interface 924. Such computer programs, when executed, enable the computer system 900 to perform the features of the present invention, as discussed herein. In particular, the computer programs, when executed, enable the processor 910 to perform the features of the present invention. Accordingly, such computer programs represent controllers of the computer system 900.
In an aspect where the invention is implemented using software, the software may be stored in a computer program product and loaded into computer system 900 using removable storage drive 914, hard drive 912, or communications interface 920. The control logic (software), when executed by the processor 904, causes the processor 904 to perform the functions of the invention as described herein. In another aspect, the invention is implemented primarily in hardware using, for example, hardware components, such as application specific integrated circuits (ASICs). Implementation of the hardware state machine so as to perform the functions described herein will be apparent to persons skilled in the relevant art(s).
In yet another aspect, the invention is implemented using a combination of both hardware and software.
The previous description is provided to enable any person skilled in the art to fully understand the full scope of the disclosure. Modifications to the various configurations disclosed herein will be readily apparent to those skilled in the art. Thus, the claims are not intended to be limited to the various aspects of the disclosure described herein, but is to be accorded the full scope consistent with the language of claims, wherein reference to an element in the singular is not intended to mean “one and only one” unless specifically so stated, but rather “one or more.” Unless specifically stated otherwise, the term “some” refers to one or more. A claim that recites at least one of a combination of elements (e.g., “at least one of A, B, or C”) refers to one or more of the recited elements (e.g., A, or B, or C, or any combination thereof). All structural and functional equivalents to the elements of the various aspects described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed under the provisions of 35 U.S.C. §112, sixth paragraph, unless the element is expressly recited using the phrase “means for” or, in the case of a method claim, the element is recited using the phrase “step for.”
While aspects of this invention have been described in conjunction with the example features outlined above, various alternatives, modifications, variations, improvements, and/or substantial equivalents, whether known or that are or may be presently unforeseen, may become apparent to those having at least ordinary skill in the art. Accordingly, the example aspects of the invention, as set forth above, are intended to be illustrative, not limiting. Various changes may be made without departing from the spirit and thereof. Therefore, aspects of the invention are intended to embrace all known or later-developed alternatives, modifications, variations, improvements, and/or substantial equivalents.
This application claims priority to U.S. Provisional Patent Application No. 61/508,402 entitled “RADIOPHARMACEUTICAL CZT SENSOR AND APPARATUS” filed on Jul. 15, 2011; and U.S. Provisional Patent Application No. 61/508,294 entitled “SYSTEMS, METHODS, AND DEVICES FOR PRODUCING, MANUFACTURING, AND CONTROL OF RADIOPHARMACEUTICALS-FULL” filed on Jul. 15, 2011. The entirety of each of the preceding applications is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3959172 | Brownell et al. | May 1976 | A |
4754786 | Roberts | Jul 1988 | A |
4777367 | Kawasaki et al. | Oct 1988 | A |
4794178 | Coenen et al. | Dec 1988 | A |
4866277 | Johnson et al. | Sep 1989 | A |
4967811 | DiGianfilippo et al. | Nov 1990 | A |
5029479 | Bryan | Jul 1991 | A |
5139731 | Hendry | Aug 1992 | A |
5171132 | Miyazaki et al. | Dec 1992 | A |
5211678 | Stephenson et al. | May 1993 | A |
5330142 | Gnau, III | Jul 1994 | A |
5356378 | Doan | Oct 1994 | A |
5373844 | Smith et al. | Dec 1994 | A |
5428470 | Labriola, II | Jun 1995 | A |
5429133 | Thurston et al. | Jul 1995 | A |
5519635 | Miyake et al. | May 1996 | A |
5527473 | Ackerman | Jun 1996 | A |
5540081 | Takeda et al. | Jul 1996 | A |
5580523 | Bard | Dec 1996 | A |
5605251 | Retti | Feb 1997 | A |
5626172 | Schumacher et al. | May 1997 | A |
5648268 | Batchelder et al. | Jul 1997 | A |
5659171 | Young et al. | Aug 1997 | A |
5800784 | Horn | Sep 1998 | A |
5866907 | Drukier et al. | Feb 1999 | A |
5911252 | Cassel | Jun 1999 | A |
5932178 | Yamazaki et al. | Aug 1999 | A |
5937364 | Westgard et al. | Aug 1999 | A |
5961458 | Carroll | Oct 1999 | A |
6021341 | Scibilia et al. | Feb 2000 | A |
6135955 | Madden et al. | Oct 2000 | A |
6172207 | Damhaut et al. | Jan 2001 | B1 |
6227809 | Forster et al. | May 2001 | B1 |
6236880 | Raylman et al. | May 2001 | B1 |
6359952 | Alvord | Mar 2002 | B1 |
6407394 | Borioli et al. | Jun 2002 | B1 |
6484050 | Carroll et al. | Nov 2002 | B1 |
6531705 | White et al. | Mar 2003 | B2 |
6559440 | Yarnall et al. | May 2003 | B2 |
6565815 | Yuan et al. | May 2003 | B1 |
6567492 | Kiselev et al. | May 2003 | B2 |
6599484 | Zigler et al. | Jul 2003 | B1 |
6624425 | Nisius et al. | Sep 2003 | B2 |
6643538 | Majewski et al. | Nov 2003 | B1 |
6644944 | Karp | Nov 2003 | B2 |
6658946 | Lipscomb et al. | Dec 2003 | B2 |
6771802 | Patt et al. | Aug 2004 | B1 |
6787786 | Kalas et al. | Sep 2004 | B2 |
6827095 | O'Connor et al. | Dec 2004 | B2 |
6828143 | Bard | Dec 2004 | B1 |
6845137 | Ruth et al. | Jan 2005 | B2 |
6915823 | Osborne et al. | Jul 2005 | B2 |
6917044 | Amini | Jul 2005 | B2 |
6986649 | Dai et al. | Jan 2006 | B2 |
6991214 | Richter | Jan 2006 | B2 |
7018614 | Kiselev et al. | Mar 2006 | B2 |
7025323 | Krulevitch et al. | Apr 2006 | B2 |
7030399 | Williamson et al. | Apr 2006 | B2 |
7056477 | Schwalbe et al. | Jun 2006 | B1 |
7104768 | Richter et al. | Sep 2006 | B2 |
7118917 | Bergh et al. | Oct 2006 | B2 |
7127023 | Wieland | Oct 2006 | B2 |
7170072 | Schwarz et al. | Jan 2007 | B2 |
7172735 | Lowe et al. | Feb 2007 | B1 |
7200198 | Wieland et al. | Apr 2007 | B2 |
7206715 | Vanderveen et al. | Apr 2007 | B2 |
7235216 | Kiselev et al. | Jun 2007 | B2 |
7279676 | Twomey | Oct 2007 | B2 |
7347617 | Pugia et al. | Mar 2008 | B2 |
7378659 | Burr et al. | May 2008 | B2 |
7418981 | Baker et al. | Sep 2008 | B2 |
7419653 | Walsh et al. | Sep 2008 | B2 |
7435392 | Oberbeck et al. | Oct 2008 | B2 |
7445650 | Weil et al. | Nov 2008 | B2 |
7445926 | Mathies et al. | Nov 2008 | B2 |
7468165 | Oberbeck et al. | Dec 2008 | B2 |
7476883 | Nutt | Jan 2009 | B2 |
7485454 | Jury et al. | Feb 2009 | B1 |
7512206 | Wieland | Mar 2009 | B2 |
7577228 | Jackson | Aug 2009 | B2 |
7586102 | Mourtada et al. | Sep 2009 | B2 |
7607641 | Yuan | Oct 2009 | B1 |
7622509 | Tonkovich et al. | Nov 2009 | B2 |
7624642 | Romo | Dec 2009 | B2 |
7634378 | Kaplit | Dec 2009 | B2 |
7638059 | Kim et al. | Dec 2009 | B2 |
7641860 | Matteo | Jan 2010 | B2 |
7659522 | Kim et al. | Feb 2010 | B2 |
7766883 | Reilly et al. | Aug 2010 | B2 |
7829032 | Van Dam et al. | Nov 2010 | B2 |
7832429 | Young et al. | Nov 2010 | B2 |
7863035 | Clemens et al. | Jan 2011 | B2 |
7917313 | Ziegler et al. | Mar 2011 | B2 |
7987726 | Dannhauer | Aug 2011 | B2 |
20010055812 | Mian et al. | Dec 2001 | A1 |
20020043638 | Kao et al. | Apr 2002 | A1 |
20020048536 | Bergh et al. | Apr 2002 | A1 |
20020128734 | Dorsett | Sep 2002 | A1 |
20020148957 | Lingren et al. | Oct 2002 | A1 |
20030007588 | Kiselev et al. | Jan 2003 | A1 |
20030034456 | McGregor | Feb 2003 | A1 |
20030057381 | Hirayanagi | Mar 2003 | A1 |
20030057391 | Krulevitch et al. | Mar 2003 | A1 |
20030175947 | Liu et al. | Sep 2003 | A1 |
20030194039 | Kiselev et al. | Oct 2003 | A1 |
20040022696 | Zigler et al. | Feb 2004 | A1 |
20040028573 | Schmitz et al. | Feb 2004 | A1 |
20040037739 | McNeely et al. | Feb 2004 | A1 |
20040054248 | Kimchy et al. | Mar 2004 | A1 |
20040084340 | Morelle et al. | May 2004 | A1 |
20040120836 | Dai et al. | Jun 2004 | A1 |
20040136878 | Meier et al. | Jul 2004 | A1 |
20040209354 | Mathies et al. | Oct 2004 | A1 |
20040258615 | Buchanan et al. | Dec 2004 | A1 |
20040262158 | Alvord et al. | Dec 2004 | A1 |
20050072946 | Studer et al. | Apr 2005 | A1 |
20050084055 | Alvord et al. | Apr 2005 | A1 |
20050147535 | Shulman et al. | Jul 2005 | A1 |
20050191184 | Vinson | Sep 2005 | A1 |
20050232387 | Padgett et al. | Oct 2005 | A1 |
20050232861 | Buchanan et al. | Oct 2005 | A1 |
20050260130 | Elmaleh et al. | Nov 2005 | A1 |
20060004491 | Welch et al. | Jan 2006 | A1 |
20060076068 | Young et al. | Apr 2006 | A1 |
20060132068 | Norling et al. | Jun 2006 | A1 |
20060150385 | Gilligan et al. | Jul 2006 | A1 |
20060231519 | Py et al. | Oct 2006 | A1 |
20060263293 | Kolb et al. | Nov 2006 | A1 |
20070027637 | Delenstarr et al. | Feb 2007 | A1 |
20070048217 | McBride et al. | Mar 2007 | A1 |
20070217561 | Wieland et al. | Sep 2007 | A1 |
20070217963 | Elizarov et al. | Sep 2007 | A1 |
20080050283 | Chou et al. | Feb 2008 | A1 |
20080064110 | Elizarov et al. | Mar 2008 | A1 |
20080122390 | Lidestri | May 2008 | A1 |
20080123808 | Caffrey | May 2008 | A1 |
20080171999 | Baplue et al. | Jul 2008 | A1 |
20080172024 | Yow | Jul 2008 | A1 |
20080177126 | Tate et al. | Jul 2008 | A1 |
20080181829 | Matteo | Jul 2008 | A1 |
20080233018 | Van Dam et al. | Sep 2008 | A1 |
20080233653 | Hess et al. | Sep 2008 | A1 |
20080249510 | Mescher et al. | Oct 2008 | A1 |
20080277591 | Shahar et al. | Nov 2008 | A1 |
20080281090 | Lee et al. | Nov 2008 | A1 |
20090005617 | Maeding et al. | Jan 2009 | A1 |
20090036668 | Elizarov et al. | Feb 2009 | A1 |
20090056822 | Young et al. | Mar 2009 | A1 |
20090056861 | Young et al. | Mar 2009 | A1 |
20090094940 | Py | Apr 2009 | A1 |
20090095635 | Elizarov et al. | Apr 2009 | A1 |
20090139310 | Santiago et al. | Jun 2009 | A1 |
20090157040 | Jacobson et al. | Jun 2009 | A1 |
20090159807 | Waller | Jun 2009 | A1 |
20090165477 | Sturken et al. | Jul 2009 | A1 |
20090181411 | Battrell et al. | Jul 2009 | A1 |
20090185955 | Nellissen | Jul 2009 | A1 |
20090218520 | Nutt | Sep 2009 | A1 |
20090247417 | Haas et al. | Oct 2009 | A1 |
20090288497 | Ziegler et al. | Nov 2009 | A1 |
20090305431 | Hodges et al. | Dec 2009 | A1 |
20090314365 | McAvoy et al. | Dec 2009 | A1 |
20090314972 | McAvoy et al. | Dec 2009 | A1 |
20100008834 | Lohf et al. | Jan 2010 | A1 |
20100101783 | Vinegar et al. | Apr 2010 | A1 |
20100145630 | Ball et al. | Jun 2010 | A1 |
20100187452 | Mukaddam et al. | Jul 2010 | A1 |
20100217011 | Dinkelborg et al. | Aug 2010 | A1 |
20100243972 | Voccia et al. | Sep 2010 | A1 |
20100286512 | Dhawale et al. | Nov 2010 | A1 |
20100304494 | Tokhtuev et al. | Dec 2010 | A1 |
20100307616 | Liou et al. | Dec 2010 | A1 |
20110003981 | Hirano et al. | Jan 2011 | A1 |
20110008215 | Elizarov et al. | Jan 2011 | A1 |
20110041935 | Zhou et al. | Feb 2011 | A1 |
20110087439 | Ziegler et al. | Apr 2011 | A1 |
20110098465 | Ball et al. | Apr 2011 | A1 |
20110126911 | Kobrin et al. | Jun 2011 | A1 |
20110150714 | Elizarov et al. | Jun 2011 | A1 |
20110178359 | Hirschman et al. | Jul 2011 | A1 |
20120074330 | Bouton et al. | Mar 2012 | A1 |
20120222774 | Husnu et al. | Sep 2012 | A1 |
20130015361 | Bouton | Jan 2013 | A1 |
20130018618 | Eshima et al. | Jan 2013 | A1 |
20130020727 | Klausing et al. | Jan 2013 | A1 |
20130022525 | Eshima et al. | Jan 2013 | A1 |
20130023657 | Klausing et al. | Jan 2013 | A1 |
20130060017 | Eshima et al. | Mar 2013 | A1 |
20130060134 | Eshima et al. | Mar 2013 | A1 |
20130102772 | Eshima et al. | Apr 2013 | A1 |
20140229152 | Chisholm | Aug 2014 | A1 |
20140238542 | Kvale | Aug 2014 | A1 |
20160001245 | Klausing et al. | Jan 2016 | A1 |
Number | Date | Country |
---|---|---|
101603929 | Dec 2009 | CN |
2059443 | Nov 2010 | EP |
WO 9512203 | May 1995 | WO |
WO 0062919 | Oct 2000 | WO |
WO 0233296 | Apr 2002 | WO |
WO 02083210 | Oct 2002 | WO |
WO 2005025519 | Mar 2005 | WO |
WO 2007041486 | Apr 2007 | WO |
WO 2008028260 | Mar 2008 | WO |
WO 2008083313 | Jul 2008 | WO |
WO 2008101305 | Aug 2008 | WO |
WO 2008128306 | Oct 2008 | WO |
WO 2009003251 | Jan 2009 | WO |
WO 2010072342 | Jul 2010 | WO |
WO-2012061353 | May 2012 | WO |
WO-2013066779 | May 2013 | WO |
WO-2014105951 | Jul 2014 | WO |
WO-2014105971 | Jul 2014 | WO |
WO-2015101542 | Jul 2015 | WO |
Entry |
---|
International Search Report dated Sep. 7, 2012. |
Pacak et al. “Synthesis of 2-Deoxy-2-fluoro-D-glucose.” Journal of the Chemical Society D: Chemical Communications, 1969, issue 2, p. 77. |
Ido et al. “Labeled 2-deoxy-D-glucose analogs, 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose.” Journal of Labelled Compounds and Radiopharmaceuticals, 1978, vol. 14, issue 2, pp. 175-183. |
Muehllehner. “Effect of Crystal Thickness on Scintillation Camera Performance.” Journal of Nuclear Medicine, 1979, vol. 20, issue 9, pp. 992-994. |
Gomzina et al. “Optimization of Automated Synthesis of 2-[18F] Fluoro-2-deoxy-D-glucose Involving Base Hydrolysis.” Radiochemistry, 2002, vol. 44, issue 4, pp. 403-409. |
GE Medical Systems Benelux s.a., “TRACERlab MX FDG,” Operator manual, Technical Publications, Direction 2335255-100, Version I, Last updated: Mar. 2003, pp. 1-61. |
Project Fact Sheet. Lab-on-a-chip implementation of production processes for new molecular Imaging agents.Universite De Liege. Http://cordis.europa.eu/fetch?CALLER=FP6—PROJ&ACTION=D&RCN=75854&DOC=. Last updated on Dec. 8, 2009, accessed on May 12, 2010, 2 pages. |
Peng et al. “Design study of a high-resolution breast-dedicated PET system built from cadmium zinc telluride detectors.” Physics in Medicine and Biology, 2010, vol. 55, issue 9, pp. 2761-2788. |
Bubble column reactor. Wikipedia, last modified on Oct. 26, 2010, accessed on May 4, 2011, 1 page. |
Lee W. Young, International Search Report & Written Opinion issued in Application No. PCT/US11/67650, mailed May 1, 2012, 11 pages. |
Blaine R. Copenheaver, International Search Report & Written Opinion issued in Application No. PCT/US12/46910, mailed Sep. 28, 2012, 8 pages. |
Lee W. Young, International Search Report & Written Opinion issued in Application No. PCT/US12/46943, mailed Sep. 28, 2012, 6 pages. |
Lee W. Young, International Search Report & Written Opinion issued in Application No. PCT/US12/46968, mailed Oct. 2, 2012, 13 pages. |
Vinke et al. “Thick monolithic scintillation crystals for TOF-PET with depth-of-interaction measurement.” IEEE Nuclear Science Symposium Conference Record, Oct. 30, 2010-Nov. 6, 2010, pp. 1981-1984. |
Blaine R. Copenheaver, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee. Issued in Application No. PCT/US12/54229, mailed Nov. 2, 2012, 2 pages. |
Lee W. Young, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee. Issued in Application No. PCT/US12/46933, mailed Dec. 3, 2012, 2 pages. |
Lee W. Young, International Search Report & Written Opinion issued in Application No. PCT/US12/46955, mailed Dec. 7, 2012, 10 pages. |
Blaine R. Copenheaver, International Search Report & Written Opinion issued in Application No. PCT/US12/54229, mailed Dec. 31, 2012, 10 pages. |
Lee W. Young, International Search Report & Written Opinion issued in Application No. PCT/US12/46933, mailed Feb. 11, 2013, 11 pages. |
Jill Warden, International Preliminary Report on Patentability. Issued in Application No. PCT/US12/46933, mailed Jul. 18, 2014, 25 pages. |
Trasis sa. “A solution for the preparation of unit doses of PET and SPECT radiopharmaceuticals.” http://www.rsllabin.com/TRASIS-DISPENSER.pdf. Revision date Oct. 2009. 8 pages. |
MacDonald, L.R. et al., “Effects of Detector Thickness on Geometric Sensitivity and Event Positioning Errors in the Rectangular PET/X Scanner,” IEEE Transactions on Nuclear Science, 2013, vol. 60 (5), pp. 3242-3252. |
Morelle J.L., et al., “Mini-fluidic chip for the total synthesis of PET tracers,” TRASIS, 2009, 6 pages. |
Wessmann S. et al., “Preparation of highly reactive [18F] fluoride without any evaporation step,” Journal of Nuclear Medicine, 2011, vol. 52 (76), pp. 1-2. |
Number | Date | Country | |
---|---|---|---|
20130015361 A1 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
61508402 | Jul 2011 | US | |
61508294 | Jul 2011 | US |